Ben Adlin is a journalist who focuses on cannabis policy and industry news. He is a writer for Marijuana Moment and his work has also been featured in FILTER. Ben covers a wide range of topics related to marijuana, including legislative updates, market trends, and scientific research.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Ben Adlin's coverage primarily focuses on marijuana legalization, drug policy, and cannabis markets in the United States. His articles often include government announcements, legal policy regulations, and cited data. To effectively pitch to Ben Adlin, one should provide insights into the latest developments related to marijuana legalization or drug policy changes in the US. Experts with a deep understanding of regulatory frameworks and market trends within the cannabis industry would likely be valuable sources for his articles. Additionally, providing access to relevant data or studies supporting new healthcare policies or pharmaceutical advancements could also capture Ben's interest due to his focus on healthcare-related topics within the context of drug policy reforms.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ben Adlin
The Drug Enforcement Administration (DEA) is arguing that a federal law giving seriously ill people the “right to try” investigational drugs doesn't apply to controlled substances like psychedelics.
By: Ben Adlin
A new settlement between the federal government and an Arizona-based nonprofit will permit the group to import and use ayahuasca as a religious
By: Ben Adlin
Authors of a new research letter published by the Journal of the American Medical Association (JAMA) on Wednesday said there's no evidence that
By: Ben Adlin
Following the failure of a Hawaii bill to legalize cannabis for adults, Gov. Josh Green (D) says he has “a possible solution” to the issue: vastly expanding the state’s existing medical marijuana system to allow people to register based on any health concern rather than needing to have one of a specific list of conditions. […]
By: Ben Adlin
A Missouri Senate committee on Wednesday stripped a proposal from a House-passed budget bill that would have funneled $10 million in state opioid settlement money to research psilocybin. An earlier version of the Republican-led proposal would have instead put the money toward the study of ibogaine as a treatment for opioid use disorder, but a […]
By: Ben Adlin
A federal judge on Thursday agreed to schedule oral arguments in a case from major U.S. marijuana companies that are seeking to shield in-state cannabis activity from federal enforcement.
By: Ben Adlin
A New Hampshire marijuana legalization bill already passed by the House of Representatives landed in a Senate committee on Thursday, where opponents of the current version—including Sen. Daryl Abbas (R) and Senate President Jeb Bradley (R)—unveiled amendments that would revise major portions of the proposal. The panel also heard three other cannabis-related measures, including a proposal […]
By: Ben Adlin
A California Senate panel this week narrowed the scope of a bill that would roll back existing employment protections for people who legally use marijuana while away from work. The revised measure, which advanced out of the committee on a 3–1 vote, would now remove those protections only for sworn law enforcement positions that involve […]
By: Ben Adlin
A new federal funding opportunity from the National Institutes of Health (NIH) will use $8.4 million to support clinical trials on the safety and efficacy of psychedelic-assisted therapy to treat chronic pain in older adults.
By: Ben Adlin
A new study on effects of frequent marijuana use challenges a number of cannabis stereotypes, with researchers finding no association with paranoia or decreased motivation among habitual users.
(833) 317-6278 